GeneDx (NASDAQ:WGS) CFO Kevin Feeley Sells 378 Shares

Key Points

• Kevin Feeley, CFO of GeneDx, sold 378 shares of the company’s stock for a total of $47,556.18, reducing his ownership by 8.45% to 4,096 shares.
• GeneDx reported earnings per share of $0.50 in its latest quarter, significantly beating analysts' expectations of $0.10, with revenue of $102.69 million compared to expectations of $86.00 million.
• Several analysts have recently upgraded GeneDx's stock ratings, with target prices raised to as high as $120.00, indicating a positive outlook for the company’s financial prospects.

GeneDx Holdings Corp. (NASDAQ:WGS - Get Free Report) CFO Kevin Feeley sold 378 shares of the company's stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $125.81, for a total value of $47,556.18. Following the sale, the chief financial officer owned 4,096 shares in the company, valued at $515,317.76. The trade was a 8.45% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Kevin Feeley also recently made the following trade(s):

• On Tuesday, July 29th, Kevin Feeley sold 388 shares of GeneDx stock. The shares were sold at an average price of $105.31, for a total value of $40,860.28.
• On Wednesday, July 9th, Kevin Feeley sold 5,278 shares of GeneDx stock. The shares were sold at an average price of $93.00, for a total value of $490,854.00.
• On Tuesday, July 1st, Kevin Feeley sold 1,344 shares of GeneDx stock. The shares were sold at an average price of $91.12, for a total value of $122,465.28.

GeneDx Trading Down 2.4%

WGS stock traded down $3.21 during mid-day trading on Monday, reaching $129.33. The company's stock had a trading volume of 442,296 shares, compared to its average volume of 658,089. The company has a current ratio of 2.87, a quick ratio of 2.70 and a debt-to-equity ratio of 0.19. GeneDx Holdings Corp. has a 12 month low of $32.11 and a 12 month high of $136.00. The business's 50 day moving average price is $104.92 and its 200 day moving average price is $91.12. The company has a market cap of $3.72 billion, a price-to-earnings ratio of 2,586.60 and a beta of 2.03.

GeneDx (NASDAQ:WGS - Get Free Report) last released its quarterly earnings data on Tuesday, July 29th. The company reported $0.50 EPS for the quarter, beating the consensus estimate of $0.10 by $0.40. GeneDx had a net margin of 0.39% and a return on equity of 16.51%. The business had revenue of $102.69 million for the quarter, compared to the consensus estimate of $86.00 million. GeneDx has set its FY 2025 guidance at EPS. On average, equities research analysts predict that GeneDx Holdings Corp. will post 0.97 EPS for the current year.

Hedge Funds Weigh In On GeneDx

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Osaic Holdings Inc. grew its position in shares of GeneDx by 54.2% during the 2nd quarter. Osaic Holdings Inc. now owns 8,835 shares of the company's stock worth $816,000 after purchasing an additional 3,106 shares in the last quarter. Thrivent Financial for Lutherans bought a new position in GeneDx during the second quarter worth $267,000. Thompson Davis & CO. Inc. raised its stake in GeneDx by 22.5% during the second quarter. Thompson Davis & CO. Inc. now owns 17,330 shares of the company's stock worth $1,600,000 after buying an additional 3,180 shares during the last quarter. Cim LLC acquired a new stake in GeneDx in the second quarter worth $440,000. Finally, Ashford Capital Management Inc. grew its holdings in shares of GeneDx by 82.1% during the second quarter. Ashford Capital Management Inc. now owns 171,526 shares of the company's stock valued at $15,834,000 after buying an additional 77,310 shares during the last quarter. 61.72% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts recently commented on the company. Guggenheim reiterated a "buy" rating and set a $115.00 price target (up from $88.00) on shares of GeneDx in a research report on Monday, June 30th. Wall Street Zen upgraded GeneDx from a "hold" rating to a "buy" rating in a report on Saturday, August 2nd. Piper Sandler set a $120.00 target price on GeneDx and gave the stock an "overweight" rating in a research note on Monday, August 4th. Finally, Wells Fargo & Company increased their target price on GeneDx from $78.00 to $95.00 and gave the stock an "equal weight" rating in a research note on Wednesday, July 30th. Six investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $101.63.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.